300 related articles for article (PubMed ID: 8901227)
1. [In vitro antimycobacterial activities of pyrazinamide analogs: results of screening tests].
Yamamoto S; Toida I; Watanabe N; Ura T
Kekkaku; 1996 Mar; 71(3):253-8. PubMed ID: 8901227
[TBL] [Abstract][Full Text] [Related]
2. In vitro antimycobacterial activities of pyrazinamide analogs.
Yamamoto S; Toida I; Watanabe N; Ura T
Antimicrob Agents Chemother; 1995 Sep; 39(9):2088-91. PubMed ID: 8540721
[TBL] [Abstract][Full Text] [Related]
3. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T
J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635
[TBL] [Abstract][Full Text] [Related]
4. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Bergmann KE; Cynamon MH; Welch JT
J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy of pulmonary Mycobacterium kansasii infection].
Mizutani S
Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of a newly developed broth microdilution test method to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for mycobacteria].
Yamane N; Nakasone I; Saitoh H; Kaneda M; Shimojima M; Yamashita K; Toyoda K; Okazawa Y
Rinsho Byori; 1998 Jul; 46(7):719-27. PubMed ID: 9721542
[TBL] [Abstract][Full Text] [Related]
7. [Determination of pyrazinamide susceptibility for Mycobacterium tuberculosis by use of Middlebrook culture media and comparison with results of pyrazinamidase test].
Yamane N; Nakasone I; Yamashita K; Toyoda K; Okazawa Y
Rinsho Byori; 1998 May; 46(5):479-85. PubMed ID: 9627500
[TBL] [Abstract][Full Text] [Related]
8. Determination of the susceptibility of Mycobacterium tuberculosis to pyrazinamide in liquid and solid media assessed by a colorimetric nitrate reductase assay.
Syre H; Øvreås K; Grewal HM
J Antimicrob Chemother; 2010 Apr; 65(4):704-12. PubMed ID: 20118493
[TBL] [Abstract][Full Text] [Related]
9. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
Kawahara S; Nagare H
Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
[TBL] [Abstract][Full Text] [Related]
10. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
11. Iron enhances the antituberculous activity of pyrazinamide.
Somoskovi A; Wade MM; Sun Z; Zhang Y
J Antimicrob Chemother; 2004 Feb; 53(2):192-6. PubMed ID: 14729751
[TBL] [Abstract][Full Text] [Related]
12. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution.
Zitko J; Paterová P; Kubíček V; Mandíková J; Trejtnar F; Kuneš J; Doležal M
Bioorg Med Chem Lett; 2013 Jan; 23(2):476-9. PubMed ID: 23237840
[TBL] [Abstract][Full Text] [Related]
14. [In vitro antimycobacterial activity of a new quinolone, T-3761].
Tomioka H; Sato K; Saito H
Kekkaku; 1995 Feb; 70(2):97-101. PubMed ID: 7699982
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antimycobacterial evaluation of N-substituted 3-aminopyrazine-2,5-dicarbonitriles.
Zitko J; Jampílek J; Dobrovolný L; Svobodová M; Kuneš J; Doležal M
Bioorg Med Chem Lett; 2012 Feb; 22(4):1598-601. PubMed ID: 22281187
[TBL] [Abstract][Full Text] [Related]
16. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
[TBL] [Abstract][Full Text] [Related]
17. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro.
Wade MM; Zhang Y
J Antimicrob Chemother; 2006 Nov; 58(5):936-41. PubMed ID: 16950824
[TBL] [Abstract][Full Text] [Related]
18. [In vitro antimycobacterial activity of a new quinolone, NM394].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311
[TBL] [Abstract][Full Text] [Related]
19. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
[TBL] [Abstract][Full Text] [Related]
20. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
Sato K; Tomioka H
Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
